Just In
- 1 hr ago Summer Fashion: Your Bollywood Style White Outfits Guide To Keep It Cool And Chic
- 2 hrs ago Sonam Kapoor Stuns In A Huisang Zhang Skirt Set, A Skirt-Top Style Guide From The OG Fashionista!
- 6 hrs ago Thrissur Pooram 2024: Date, Time, History, Significance, And Celebrations Related To Kerala's Rich Traditions
- 9 hrs ago Daily Horoscope, 19 April 2024: Gemini Will Have A Controversial Day In Terms Of Love
Don't Miss
- News Euro Zone Economy Faces Risks Without Interest Rate Cuts: ECB Member Warns
- Sports IPL 2024: More pressure on Hardik Pandya as Dale Steyn suggests MI captain to step up and help Jasprit Bumrah
- Movies Coachella: AP Dhillon's Tribute To Sidhu Moosewala Goes Viral Amid Guitar Controversy, Fans REACT To VIDEO
- Technology Vivo V30e Launch Date in India set for May 2: Flipkart Availability Confirmed
- Finance Rs 14/Share Dividend: Stockbroking Co To Consider Bonus Share, Shares Up 126% In 180-Days
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
- Education IIIT-Bangalore Introduces PG Diploma In Digital Product Design And Management
- Automobiles Jawa Yezdi Expands Mega Service Camps To 32 New Cities, Focusing On Tier-II And Tier-III Regions
Covaxin Shows 50% Effectiveness Against Symptomatic Covid-19 In Real-World Assessment: Lancet Study
The results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases. Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart.
In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The World Health Organization (WHO) added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. The latest study was conducted during India's second COVID-19 surge and in healthcare workers who were primarily offered Covaxin.
The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees. Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection. Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2, the virus that causes COVID-19, and 1,097 tested negative.
Positive cases were matched to negative RT-PCR tests (controls). The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates.
The study found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent. The effectiveness of two vaccine doses remained stable over the seven-week follow-up period, the researchers said.
The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said.
The authors acknowledge that the vaccine effectiveness of Covaxin estimated in this study is lower than the efficacy reported by the recently published phase 3 trial. They noted that several factors may be responsible for the lower vaccine effectiveness in the latest study.
The researchers said this study population only included hospital employees who may have a higher risk of exposure to COVID-19 infection than the general population. The research was conducted during the peak of India's second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said.
Photo Credit: Background vector created by Kerfin7 - www.freepik.com
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- kidsCovid-19 Vaccines For Kids: DCGI Grants Emergency Use Nod To 3 Vaccines For Different Age Group Of Children
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessIndia's Covaxin To Be Evaluated As COVID-19 Vaccine Candidate In USA
- healthCovaxin Granted Emergency Use Listing In 13 Nations As On Jan 31 According To WHO: Government
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthGovt's Decision On COVID-19 Vaccination For Children 'Unscientific': Senior AIIMS Epidemiologist
- healthCovaxin's Shelf Life Extended To 12 Months From Date Of Manufacture
- healthExperts Allay Covaxin Concerns, Say 50% Effectiveness Against Delta-Driven COVID-19 Surge Not Bad
- healthGovernment Nod To Commercial Export Of Covishield, Covaxin In View Of Sufficient Stock